Forbion

Forbion celebrates success fourth closed end fund by sounding the gong

Sander Slootweg, Managing Partner at Forbion, one of the high profile VC investment firms in Europe, opens trading..

Forbion recently announced the final close of its new flagship fund, Forbion IV. The fund closed above its original target at EUR 360 million and was significantly oversubscribed. With this new fund under its belt, Forbion intends to build and invest in around 15 companies, which develop new medicines for high and unmet medical needs, impacting patients’ lives. These development-stage companies will be either acquired by strategic buyers like major pharma or biotech companies or will be listed on an exchange.

For more Information: www.forbion.com

Download photo